Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subject: RTG

VOTI Detection Announces Closing of Shares for Debt Transaction


MONTREAL, May 13, 2021 /CNW Telbec/ - VOTI Detection Inc. ("VOTI" or the "Company") (TSXV: VOTI), a leading-edge Canadian technology company that develops latest-generation X-ray security systems based on 3D Perspectivetm technology, today announced that it has completed its previously announced shares for debt transaction with holders of Convertible Debenture Units of the Company (see press release dated May 6, 2021). At the closing, VOTI issued to the participating holders a total of 8,906,392 common shares of the Company and warrants to purchase an aggregate of 4,333,333 common shares of the Company, each warrant being  exercisable at $0.55 per share on or before May 13, 2024.   The Convertible Debentures Units of the participating holders, comprised of convertible debentures in the total principal amount of $3,640,000 and warrants to purchase a total of 2,184,000 common shares, have been cancelled.

All securities issued under this transaction are subject to a four month hold period.  

About VOTI Detection

VOTI Detection, headquartered in Montreal, Quebec, and listed on the TSX Venture Exchange, is a leading-edge Canadian technology company that develops latest-generation X-ray security systems based on 3D Perspectivetm technology. VOTI's technology produces remarkably sharp and more revealing X-ray images that are competitively superior while delivering enhanced threat detection capabilities and an improved user experience. Since its inception, VOTI has installed scanners in more than 50 countries and has consulted heavily with government agencies and security specialists worldwide to develop feature-rich and easy-to-use scanners that meet the sophisticated needs of modern security screening operations.  www.votidetection.com

Notice regarding forward-looking statements:

This release includes forward-looking information within the meaning of Canadian securities laws regarding VOTI Detection and its business. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of VOTI Detection, and are based on assumptions and subject to risks and uncertainties. Although the management of VOTI Detection believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the threat detection technology industry, failure to obtain regulatory approvals, economic factors, management's ability to manage and to operate the business of VOTI Detection, the equity markets generally and risks associated with growth and competition. Although VOTI Detection has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and VOTI Detection does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. In addition, the current situation and future developments with respect to the COVID-19 pandemic could cause certain of the assumptions and information set forth herein or the fact that on which such assumptions are based to differ materially from previous expectations including in respect of demand for our products, supply chain and availability of materials, mobility and shipping of materials and or products, access to debt and equity capital and other factors.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VOTI Detection Inc.


These press releases may also interest you

at 08:20
Intercontinental Exchange, Inc. ("ICE") announced today that as of 5:00 p.m., New York City time, on May 16, 2024 (the "Early Tender Deadline"), $997.4 million in aggregate principal amount of outstanding 3.625% Senior Notes due 2028 (CUSIP:...

at 08:10
Guardant Health, Inc. , a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of...

at 08:08
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center ("VEC") is writing to provide information regarding an event that involves certain information relating to personal health information.  On March 21, 2024, VEC became aware that...

at 08:05
CCC Intelligent Solutions Holdings Inc. (CCC) , a leading cloud platform powering the P&C insurance economy, today announced that management will present at the following investor conferences: The J.P. Morgan Global Technology, Media and...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 17,...

at 08:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role...



News published on and distributed by: